Screening methods for identifying compounds that regulate skeletal muscle
atrophy or hypertrophy, regulate the activity or expression of the
vasoactive intestinal peptide receptors (VPAC) or regulate expression of
vasoactive intestinal peptide (VIP) or VIP analogs are provided. Methods
for the prophylactic or therapeutic treatment of skeletal muscle atrophy
utilizing VPAC as the target for intervention are described.
